

European Academy of Dermatology and Venereology

JOINT STATEMENT

Addressing Skin Cancer Prevention across the EU

ENDORSED BY



































Organizations













NATIONAL SOCIETIES

Albanian Dermatology and Venereology Association

Austrian Society of Dermatology and Venereology

Belarusian Society of Dermatovenereologists and Cosmetologists

Royal Belgian Society of Dermatology & Venereology

Psoriasis Association of Bosnia and Herzegovina

Croatian Dermatovenereological Society of the Croatian Medical Association

Cyprus Dermatology and Venereology Society

Czech Dermatovenereological Society

The Danish Dermatological Society

Estonian Society for Dermatovenereologists

Finnish Dermatological Society

French Society of Dermatology

German Dermatological Society

Hellenic Society of Dermatology and Venereology

Jens Gieseke

Hungarian Dermatological Society

Icelandic Dermatological Society

Irish Association of Dermatologists





Hilde Vautmans

Italian Society of Medical, Surgical and Cosmetic Dermatology and of Sexually Transmitted Diseases Lithuanian Association of Dermatovenereologists Maltese Association of Dermatology & Venereology Montenegrin Association of Dermatovenereology Macedonian Dermatovenereologic Society Norwegian Society of Dermatology and Venereology Polish Dermatological Society Portuguese Society of Dermatology and Venereology Portuguese Skin Cancer Association Serbian Association of Dermatovenereologists Slovak Dermatovenereological Society Association of Slovenian Dermatovenereologists

MEMBERS OF THE EUROPEAN PARLIAMENT

Spanish Academy of Dermatology and Venereology

Swedish Society for Dermatology and Venereology

Swiss Society of Dermatology and Venereology

Dutch Society of Dermatology and Venereology

Turkish Society of Dermatology **British Association of Dermatologists** Skin cancer¹ is among the most common and burdensome types of cancers in the European Union. In 2020, over 106.000 EU citizens were diagnosed with melanoma², making it the sixth most frequently occurring cancer and one of the twenty most frequent causes of cancer death³. Keratinocyte Carcinomas⁴ (which include basal cell and squamous cell carcinomas) are by far the most widespread of all cancers and whilst not life-threatening in most cases, can significantly impact a patient's quality of life⁵. It is of major concern that Keratinocyte Carcinomas are the most rapidly increasing cancers, with incidence expected to continue rising (by over 40% until 2040)⁶, presenting a tremendous challenge to health systems. This does not have to be the case, as skin cancer is part of the 40 percent of cancers that are preventable⁷ and whose incidence would be considerably reduced if more conscious and responsible behaviours were adopted.

Europe's Beating Cancer Plan is an important opportunity to join forces towards developing an adequate EU policy and regulatory framework to address skin cancer. With a view to improving skin cancer prevention across Europe, the signatory organisations call on the European Commission to act on several areas where additional measures are needed:

1. IMPROVING UNDERSTANDING, EDUCATION AND AWARENESS ABOUT SKIN CANCER AND IMPLEMENTING EVIDENCE-BASED INTERVENTIONS FOR BEHAVIOURAL CHANGE



Educating citizens about the risks of skin cancer from excessive exposure to natural and artificial UV radiation (e.g. sunbeds) is crucial to effectively reduce the incidence of the disease. Particular attention is needed to reach vulnerable populations (children and teenagers, outdoor workers and people with high risk factors or conditions which predispose them to skin cancer). A personalised approach to prevention, whereby tailored messages are delivered to target populations at the right time for them, can improve understanding and awareness, and together with the implementation of evidence-based interventions, foster more conscious and responsible behaviours.

The co-signatories call on the European Commission to:

- Update the **European Code Against Cancer** considering the latest scientific evidence and best practices in skin cancer prevention
- Make **skin cancer prevention information widely available** to EU citizens and healthcare professionals
- Facilitate the uptake of **scientifically-validated interventions** including digital and innovative tools
- Encourage the setting up of **EU-wide awareness-raising campaigns** on skin cancer prevention, to:
 - Promote the **protection of children and teenagers** during organised recreational activities (e.g. in schools, kindergartens, sport clubs etc.)
 - Promote adequate **skin protection to outdoor workers** as well as to all citizens participating in outdoor pursuits (e.g. sports, tourism, sunbathing)
 - Improve understanding of the **harmful effects of sunbeds**
- Improve understanding, importance and implementation of the **HPV vaccination campaign** as the long-term prevention tool of different Keratinocyte Carcinomas
- Allocate EU funds (e.g. through the EU4Health Programme and Horizon Europe) to support understanding, education and awareness about skin cancer and sun exposure behaviours, and in particular to address inequalities

¹ Includes all cancers that appear on the skin and mucosa

² Most recent estimates from the European Cancer Information System (ECIS) for the EU-27 countries on melanoma skin cancer incidence and mortality

³ European Cancer Information System (ECIS) Melanoma Factsheet, 2021

⁴ The term non melanoma skin cancer (NMSC) covers all cutaneous cancers that do not involve melanocytes. This term is widely (and inconveniently) used to refer to basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). Keratinocyte Carcinomas (KC), named from the cell of origin (similarly to melanoma) is a more correct term for grouping BCC and SCC, the most frequent skin cancers

⁵ Other skin cancers exist, including Merkel cell carcinoma, skin lymphomas, adnexal carcinomas etc. and while rare, can have high mortality 6 Girvalaki C et al, Non-melanoma skin cancer as an occupational disease. What is the impact on the society and the welfare system? Journal of Health Inequalities (2020); 6(2) 153-159

⁷ Communication from the Commission to the European Parliament and the Council: Europe's Beating Cancer Plan (2021)

2. INTRODUCING MEASURES TO PROTECT EU CITIZENS FROM EXCESSIVE EXPOSURE TO NATURAL AND ARTIFICIAL UV RADIATION



Excessive exposure to natural and artificial UV radiation is the main cause of skin cancer. Children and teenagers are particularly vulnerable, as their lifestyle exposes them to greater risks: they spend more time outdoors and usually are not aware of the harmful effects of UV radiation. Artificial tanning devices (e.g. sunbeds) play a significant role in the development of skin cancer: over 3,400 melanoma cases are attributable to sunbed use every year in Europe and there is evidence that sunbed use substantially increases the risk of Keratinocyte Carcinomas. Despite UV radiation being classified by the World Health Organisation International Agency for Research on Cancer (IARC) as carcinogenic to humans⁸, there are still no EU harmonised rules regulating sunbed use.

The co-signatories call on the European Commission to:

- Develop legislative/policy measures and recommendations that improve adoption of skin cancer preventative behaviours
- Develop or update a set of recommendations for Member States on adequate sun protection measures for **children and teenagers in institutional settings**, for instance during school hours and organised outdoor activities
- Implement strict criteria and monitoring in the **access and use of sunbeds**, including banning their use by minors and a phasing out for aesthetic purposes
- Regulate sunbeds as medical devices, not as consumer products

3. RECOGNISING SKIN CANCER AS AN OCCUPATIONAL DISEASE AND IMPLEMENTING UV PROTECTION MEASURES FOR OUTDOOR WORKERS



In the EU, 14.5 million people work outdoors for at least 75 percent of their working time⁹, dramatically increasing the risk of developing skin cancer. Although skin cancer is the most common occupational cancer in Europe, it is not recognised as such within the EU regulatory framework, even though recent UV-measurements have shown that outdoor workers all over Europe are regularly exceeding the daily WHO/ICNIRP¹⁰ UV-exposure limits by up to five times¹¹.

The co-signatories call on the European Commission to:

- Ensure **official recognition of UV-induced Keratinocyte Carcinomas**, including actinic keratosis, as an occupational disease
- **Update EU Directives** to recognise natural UV radiation as an **occupational risk factor** and the risk of skin cancer as an **occupational disease**, namely:
 - Annex I, Part 5 of <u>Commission Recommendation (2003/670/EC) on the European schedule of occupational disease</u> to reflect the direct link between outdoor work and skin cancer caused by solar UV radiation
 - Directive 2006/25/EC on artificial UV radiation, which must be expanded for solar UV
- Provide guidance to Member States on **UV protection measures for outdoor workers**, such as:
 - **Schedules** avoiding workers' exposure during sun peak hours (also to avoid heat stroke)
 - Facilitating access to regular screening and monitoring for outdoor workers
 - Implementing **education of the risks of UV exposure** for both employers and employees

⁸ www.who.int

⁹ Girvalaki C et al, Non-melanoma skin cancer as an occupational disease. What is the impact on the society and the welfare system? Journal of Health Inequalities (2020); 6(2) 153-159

¹⁰ International Commission on Non-Ionising Radiation Protection

¹¹ John SM, Garbe C, French LE, Takala J, Yared W, Cardone A, Gehring R, Spahn A, Stratigos A. Improved protection of outdoor workers from solar ultraviolet radiation: position statement. J Eur Acad Dermatol Venereol. 2021 Jun;35(6):1278-1284. doi: 10.1111/jdv.17011. Epub 2020 Nov 21. PMID: 33222341

4. IMPROVING REGISTRATION OF SKIN CANCER CASES ACROSS EUROPE TO DETECT RISK GROUPS



Cancer registries provide the epidemiological data needed to estimate cancer burden in a given population and to inform decision-making on resource allocation according to public health priorities and needs. Inadequate registration of melanoma cases in several European countries means that disease burden is underestimated. Furthermore, Keratinocyte Carcinomas are not reported in most population-based cancer registries and when they are, they are grouped under a single coding, preventing differentiation between tumour types.

The lack of effective and harmonised registration of melanoma and Keratinocyte Carcinomas across Europe prevents adequate data collection and constitutes an obstacle for the development of targeted skin cancer control measures.

The co-signatories call on the European Commission to:

- Take measures to facilitate **improved registration of melanoma cases** across the EU, particularly in South-East Europe
- Promote the inclusion of **Keratinocyte Carcinomas** reporting in **population-based cancer registries** with clearly distinguished datasets for separate diseases according to international cancer classification systems

5. ENHANCING EARLY DETECTION OF SKIN CANCER BY TARGETED SCREENING OF HIGH RISK GROUPS



Targeted cancer screening programmes help identify cases amongst high-risk population groups, helping to tackle the disease promptly and cost-effectively. Therefore, the Commission's plans to update the Council Recommendation on cancer screening and to widen the scope of targeted cancer screenings to additional types of cancers other than cervical, breast and colorectal cancers, are of utmost importance.

The co-signatories call on the European Commission to:

- Expand the scope of EU-wide cancer screening to include melanoma and Keratinocyte Carcinomas, targeting high-risk groups, including individuals aged above 60 years, patients with a history of melanoma or Keratinocyte Carcinomas, individuals with multiple nevi and/or fair skin, immunosuppressed patients and individuals with cumulative burden of UV exposure, such as outdoor workers
- Support **research** into and the development of **skin cancer screening methods**, particularly with new technologies

This joint statement is an initiative driven and funded by the European Academy of Dermatology and Venereology as part of its EU Advocacy programme of activities.

For more information on EADV, visit eadv.org







